<DOC>
	<DOCNO>NCT00375726</DOCNO>
	<brief_summary>Dengue fever , cause dengue virus , major health problem tropical subtropical region world . The purpose study test safety immune response new dengue virus vaccine healthy adult .</brief_summary>
	<brief_title>Safety Immune Response Dengue Virus Vaccine ( rDEN3/4delta30ME ) Healthy Adults</brief_title>
	<detailed_description>Dengue virus , cause dengue fever dengue shock syndrome , major cause morbidity mortality several world 's tropical subtropical region . The rDEN3/4delta30 ( ME ) vaccine live attenuate dengue virus vaccine may protective dengue virus serotype 3 ( DEN3 ) . The purpose study evaluate safety immunogenicity rDEN3/4delta30 ( ME ) vaccine healthy adult . This study last 40 week . Participants randomly assign receive one three dos rDEN3/4delta30 ( ME ) placebo . Participants Group 1 receive middle dose rDEN3/4delta30 ( ME ) placebo study entry . Group 2a begin enrollment immunogenicity review participant Group 1 . Participants Group 2a receive high dose rDEN4delta30 ( ME ) placebo study entry . Group 2b begin enrollment immunogenicity review participant Group 2a . Participants Group 2b receive lowest dose rDEN4delta30 ( ME ) placebo . After vaccination , participant group follow closely every day first 16 day study . Participants take temperature three time day Day 16 record measurement diary . After Day 16 , participant study visit Days 21 , 28 , 42 , 180 ; physical exam blood collection occur visit . Some participant may ask join skin biopsy substudy .</detailed_description>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Good general health Available duration study Willing use acceptable form contraception duration study Significant neurologic , heart , lung , liver , rheumatologic , autoimmune , kidney disease Behavioral , cognitive , psychiatric disease , opinion investigator , may interfere study Significant laboratory abnormality Medical , work , family problem result alcohol illegal drug use within 12 month prior study entry History severe allergic reaction anaphylaxis Emergency room visit hospitalization severe asthma within 6 month prior study entry HIV1 infect Hepatitis C virus ( HCV ) infect Hepatitis B surface antigen positive Immunodeficiency syndrome Use corticosteroid immunosuppressive medication within 30 day prior study entry . Participants use topical nasal corticosteroid exclude . Live vaccine within 4 week prior study entry Killed vaccine within 2 week prior study entry Absence spleen Blood product within 6 month prior study entry Previous dengue virus flavivirus ( e.g. , yellow fever virus , St. Louis encephalitis , West Nile virus ) infection Previously receive yellow fever dengue vaccine Plans travel area dengue infection common Received investigational agent within 30 day prior study entry Other condition , opinion investigator , would interfere study Pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Dengue Fever</keyword>
	<keyword>Dengue Vaccine</keyword>
	<keyword>Dengue Virus</keyword>
	<keyword>Dengue Hemorrhagic Fever</keyword>
	<keyword>Dengue Shock Syndrome</keyword>
</DOC>